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Resumo 
 
A Interleucina 10 (IL-10) é uma citoquina anti-inflamatória que modela a 
resposta imunitária, sendo crucial para a homeostasia do sistema imune. A 
desregulação da sinalização da IL-10, e receptor da IL-10, está associada com 
inúmeras patologias, especificamente infeções crónicas e doenças carácter 
autoimune. Recentemente, o nosso laboratório situou a IL-10 como reguladora da 
hematopoiese. De facto, uma sobre-expressão de IL-10 conduz a uma aberrante 
mielopoiese, com a simultânea diminuição na limfopoiese, e ocorrência de 
hematopoiese extramedular. No entanto, os mecanismos moleculares pelos quais a 
IL-10 desregula e hematopoiese continuam indefinidos. Este projeto tinha como 
objectivo a investigação das vias moleculares que orquestram a mieloproliferação 
associada à IL-10. Recorrendo a um modelo animal que sobre-expressa IL-10 de 
uma forma indutível (o murganho pMT-10) e a uma série de ferramentas 
laboratoriais, que incluem inibidores químicos das vias moleculares, nós 
descobrimos que a desregulação na hematopoiese é sinalizada sobretudo via PI3K. 
Adicionalmente, propusemos que anómala mieloproliferação dirigida pela sobre-
expressão de IL-10 dá origem a uma patologia semelhante à leucemia 
mielomonocítica crónica humana, uma doença frequentemente associada com o 
envelhecimento. Surpreendentemente, também observamos que uma contínua 
sobre-expressão de IL-10 promove o surgimento in vivo de características 
progeroides, culminando com a morte prematura dos murganhos. Estas observação 
levaram à hipótese da IL-10 estar a induzir senescência. Portanto, de forma a avaliar 
o possível papel para a IL-10 na senescência celular, nós estabelecemos culturas 
primárias de fibroblastos, estimuladas com IL-10 recombinante, e medimos a 
atividade de β- galactosidase – um marcador de senescência –, e a ativação de p21 
– um marcador para a paragem do ciclo celular. Resultados preliminares indicam a 
IL-10 de facto como um indutor de senescência. Em conclusão, o trabalho 
apresentado nesta dissertação estabeleceu que a mieloproliferação induzida pela IL-
10 é dependente da via molecular PI3K, apresentando também o pMT-10 como um 
possível modelo para indução de leucemia mielomonocítica crónica e 
envelhecimento premature.  
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1. Abstract 
 
 
 Interleukin (IL)-10 is anti-inflammatory cytokine that functions as a modulator 
of the immune response, being thereby crucial for the homeostasis of the immune 
system. Deregulation of the IL-10/IL-10 receptor signaling has been associated with 
many pathologies, specifically autoimmune diseases and chronic infections. 
Recently, our lab placed IL-10 as a regulator of hematopoiesis. Indeed, an 
overexpression of IL-10 leads to aberrant myelopoiesis, with concomitant decrease 
in lymphopoiesis, and presence of extramedullary hematopoiesis. However, the 
molecular mechanisms by which IL-10 deregulates hematopoiesis remain elusive. 
This thesis aimed to investigate the molecular pathways orchestrating the IL-10-
induced myeloproliferation. By resorting to the animal model for inducible IL-10 
overexpression (the pMT-10 mouse) and to a series of tools, including chemical 
inhibitors of signaling pathways, we found that the deregulated hematopoiesis was 
mainly signaled via the PI3K pathway. Additionally, we propose that the observed IL-
10-driven aberrant myelopoiesis gives rise to a pathology that resembles the human 
chronic myelomonocytic leukemia, a disease frequently associated with aging. 
Surprisingly, we also observed that a sustained IL-10 overexpression led to the in 
vivo emergence of progeroid features, culminating with the mice premature dead. 
Altogether, these observations led to the hypothesis that IL-10 might be inducing 
senescence. To evaluate a possible role for IL-10 in cellular senescence, we cultured 
mouse primary fibroblasts with recombinant IL-10 and measured the activity of β-
galactosidase – a marker for senescence –, and the activation of p21 – a marker for 
cell cycle arrest. Preliminary data point to IL-10 as a senescence inducer, via cell 
cycle arrest. Future work will be performed to better explore the contribution of IL-10 
to cellular senescence. In conclusion, the work presented in this thesis established 
that IL-10-induced myeloproliferation is dependent on PI3K signaling pathway, and 
assigned the pMT-10 as a possible model for immune-induced chronic 
myelomonocytic leukemia and premature aging.  
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2. Introduction 
 
2.1. Hematopoiesis 
 
Circulating blood cells are not only critical to replenish nutrients and oxygen to 
tissues, but also play a central role ensuring the organism immunity. Hematopoiesis 
is the process by which all blood cells are differentiated from hematopoietic stem 
cells (HSCs), throughout the lifetime of the individual. HSCs, a rare population 
residing in the bone marrow (BM), are able to self-renew, which denote them as long-
lived (1). HSCs are also multipotent, proceeding to a hierarchical differentiation and 
thus giving rise to various blood cell populations, such as lymphocytes, granulocytes, 
monocytes, erythrocytes and platelets, which are mostly short-lived and need to be 
replenished (2). Importantly, defects along the hematopoietic process may lead to 
life-threatening diseases (3).  
To understand the extent and complexity of hematopoiesis and cell fate 
commitment, the origin of the hematopoietic system needs to be considered. The 
production of blood cells starts in early stages during the embryonic development. It 
is believed that the yolk sac is the first site for hematopoiesis, followed by the aorta-
gonad mesonephros region, the fetal liver, and finally, after birth, the BM (4). The first 
wave for blood production plays the main goal of generating red blood cells, in order 
to facilitate tissue oxygenation during embryo growth (5). Definitive hematopoiesis 
involves HSC migration and colonization of the fetal liver, thymus, spleen and finally 
BM (6). The timeline of events is inconsonant, since some authors argue that HSCs 
of the fetal liver circulate to the adult BM (7), and others observe that both fetal liver 
and BM are seeded during the same stage of development (8). Interactions between 
early lymphocytes entering the developing thymus – “thymic crosstalk” – shed some 
light on the possible role of myeloid and lymphoid progenitors in stimulating the 
growth of secondary hematopoietic sites (9). In conclusion, the establishment of a 
primitive immune system is thought to be achieved through a stepwise hematopoietic 
process, involving an already well-defined genetic program (10). 
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 Hematopoiesis occurs in an orderly fashion in which HSCs generate 
progenitors and subsequently precursor cells, following a cellular fate commitment. 
The classical model for hematopoietic lineage branching is well established, where 
two major progenitor populations are defined: common lymphoid progenitors (CLPs), 
giving rise to precursors and mature B and T cells, and Natural Killer (NK) lineage 
cells; and common myeloid progenitors (CMPs), that generate megakaryocyte-
erythrocyte progenitors (MEPs) and granulocyte-macrophage progenitors (GMPs) 
(11). MEPs further differentiate into megakaryocytes and erythrocytes, whereas 
GMPs generate neuthrophils, eosinophils, basophils and monocytes (11). Figure 1 
illustrates a simplified representation of the hematopoietic tree. Notably, lineage 
commitment is not static as there are numerous reports demonstrating that 
committed hematopoietic cells can be re-programmed and converted into cells of 
other lineages (12). 
 
		
Figure 1. Representation of the hematopoietic tree. Long-term hematopoietic stem cells (LT-
HSCs) have the potential for self-renewing and differentiating into more mature cells. In the BM, 
short-term (ST) HSCs differentiate into progenitor cells common lymphoid precursors (CLPs), 
common myeloid precursors (CMPs), granulocyte-monocytic precursors (GMPs) and 
megakaryocyte-erythrocyte precursors (MEPs), according to the organism requirements. HSCs and 
precursors are represented within the purple diagram. Mature hematopoietic cells, represented 
within the salmon diagram, are found throughout the circulatory system and within tissues. 
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Every cellular population of the hematopoietic tree is defined and 
characterized based on the expression of surface markers (1). The identification of 
HSCs from BM cellular suspensions is usually determined by the surface expression 
of Sca-1 and c-kit, within the Lin- fraction. Thus, HSCs are within the Lin-Sca+ckit+ 
(LSK) cellular population. Some authors further subdivide HSCs into long-term 
HSCs, short-term repopulating HSCs and multipotent progenitors (MPPs), being the 
latter a population without self-renewal ability, but with its differentiation potential still 
conserved (13). Typically, short-term HSCs and MPPs retain LSK markers, but 
additionally express FMS-like tyrosine kinase (Flt3) (14). Further into the 
hematopoietic tree, interleukin(IL)-7Rα is a characteristic marker expressed on CLPs 
and early B and T cells progenitors (15), whereas the distinctive marker for CMPs is 
CD34, which allows the distinction between GMPs, CMPs and MEPs. Mature 
hematopoietic cells also express characteristic surface markers; for instance, cells of 
myeloid nature are defined as CD11b positive (16), early and pro B cells both 
express CD19 (17), and T cells can be classified as CD4 or CD8 positive (18). As the 
hematopoietic tree starts to branch, the cellular pluripotency gives rise to the 
multipotency of the hematopoietic progenitors, from which the mature cells are 
differentiated. Eventually mature cells leave the BM and enter the circulating system 
(19). In contrast to all other lineages, that are exclusively BM-derived, T cells 
differentiate after migration of its progenitors into the thymus (20). After the 
maturation process, T lymphocytes also enter the bloodstream, and migrate to 
peripheral lymphoid organs.  
 
The most abundant population of mature immune cells is of myeloid nature (21). 
Terminal populations of the myelopoietic tree such as macrophages, granulocytes 
and dendritic cells are of great importance due to their role in protecting the organism 
against pathogens, eliminating dying cells, and regulating tissue remodeling. During 
tumor progression, myeloid cells play functions associated with angiogenesis, 
metastasis and invasion (22). The differentiation state of a cell can be also defined by 
the tissue and microenvironment (23); for instance, tissue-resident macrophages are 
cells derived from monocytes that are in circulation in the peripheral blood, moreover, 
according to the microenvironment and organism requirements they can be polarized 
into M1, M2 or even tumor-associated macrophages (24). Of all granulocytes, the 
most ample population is the neutrophils; they have a potent microbicidal activity own 
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to their phagocytic capacity. In basal state, neutrophils are only released from the BM 
after conclusion of their maturation process (25); nevertheless, during infections, 
neutrophil precursors might be releases in order to augment the organism response. 
Because the differentiation of hematopoietic precursors into mature cells allows 
immune surveillance of the organism and efficient control of infections and 
inflammation, the regulation of the differentiation process needs to be tight and 
competent. Given that the main focus of this thesis is myelopoiesis, the upcoming 
sections will be centered on better describing this branch of the hematopoiesis.	
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2.2. Factors Regulating Hematopoiesis 
 
Hematopoietic cell differentiation and commitment is a complex process 
mediated by several transcription factors, direct cell-cell interactions, environmental 
cues and cytokines (2). The impact of these elements can be instructive, thus directly 
affecting cell fate commitment and differentiation, or permissive, by supporting cell 
survival and/or expansion of progenitors already pre-committed. Of most relevance, 
transcriptional factors and cytokines are the better-studied regulators of 
hematopoiesis. 
 
2.2.1. Transcription Factors 
 
The processes leading to lymphoid or myeloid differentiation require deep 
changes in gene expression, and these are associated with regulatory networks of 
transcription factors (26).  
Two well-known transcription factors for progenitor cells are Ikaros and 
Purine Rich Box-1 (PU.1). The Ikaros family of proteins is characterized by the 
presence of zinc finger motifs along their aminoacidic chain (27). These proteins 
orchestrate their role as hematopoietic regulators since early embryonic stages, and 
continue during adulthood (28). Mutations on several members of Ikaros family often 
result in hematological malignances, mainly of lymphoid nature, as mutated mice 
show a defective lymphopoiesis (29). PU.1 although also critical for the generation of 
progenitor B and T lymphocytes, is essential for myeloid cell differentiation and HSC 
maintenance (30). Its broad role was firstly attested by the observation that PU.1 null 
mice die at birth and display absence of myeloid and lymphoid cells (31). 
Several transcription factors play a role in specific lineage commitment. 
Within the myeloid branch, CCAAT/enhancer-binding protein alpha (C/EBPα) is a key 
transcription factor for granuloytic-macrophage commitment. Indeed, mice defective 
for C/EBPα show insufficiency in neutrophils and eosinophils generation (32). It has 
been proposed that this factor acts in early stages of differentiation, since the 
deletion of C/EBPα by retroviral expression did not affect terminal differentiation of 
GMPs (33). Another important transcription factor is IFN regulatory factor 8 (IRF-8), 
which acts on the myeloid lineage by repressing the development of neutrophils and 
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promoting the emergence of dendritic cells (34). For the megakaryocytic-erythroid 
lineage, the most prominent transcription factors are GATA-1, Kruppel-like factor 1 
(KLF1) and GFI1b (Growth factor independence 1). Indeed, deficiency in GATA-1 
blocks the development of erythroid cells in embryos leading to lethal anemia (35); 
GATA-1 is also essential to the maturation of megakaryocytes. KLF1, being essential 
to erythropoiesis, is present in both precursor and definitive erythroid populations; 
similar to GATA-1, ablation of the KLF1-encoding gene leads to lethal anemia in 
embryos (36). Finally, GFI1b is expressed essentially in erythroid and 
megakaryocytic precursors (37), as in conditional GFI1b knockout mice the 
differentiation from pro-erythroblasts to mature erythroblast is substantial decreased 
(38). Of note, GFI plays a broad role in diseases such as neutropenia, myeloid 
leukemias or even allergies. In addition to myeloid promoting transcription factors, 
some of these molecules counter-balance myelopoiesis. This is for example the case 
for monocytic transcription factor MafB limits the ability of macrophage colony-
stimulating factor (M-CSF) to induce myeloid commitment in HSCs (39). 
These transcription factors do not work as sole elements. Indeed, lineage 
commitment and differentiation is an elaborate process and it requires an entangled 
network of components. For instance, the modulation of the myeloid-associated 
transcription factors depends on several cellular processes, such as those resulting 
from communication through cytokines. 
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2.2.2. Cytokines 
 
Studies assessing the role of cytokines and cytokine receptors, on 
hematopoietic cells, suggest that these molecules likely play a permissive effect. This 
is for example illustrated by the observation that mice deficient for IL-2, IL-3 or IL-17. 
IL-2 – important for the regulation of the activation of T lymphocytes – plays a role in 
myelopoiesis, as mice with IL-2 deficiency develop anemia but maintain normal 
levels of peripheral blood leukocytes (40). Chen et al. studied the hematopoietic 
process in older mice defective for IL-2, and observed an overall hematological 
failure, with the development of anemia, lymphocytopenia, thrombocytopenia, 
splenomegaly, and thymus involution (41). IL-3 is a well-documented cytokine in 
contributing to differentiation of hematopoietic progenitor cells and maturation of 
myeloid cells (42). Moreover, IL-3 seems to be relevant for survival and proliferation 
of HSCs, a study from Robin et al. displayed the importance of IL-3 during the 
development of HSCs by amplifying and regulating the HSCs pool (43). IL-17 is also 
a potent mediator of hematopoietic responses, as it induces the production of 
relevant cytokines such as granulocyte-macrophage colony-stimulating factor (GM-
CSF) and granulocyte colony-stimulating factor (G-CSF) (44). During in vivo 
overexpression of murine IL-17, the granulopoeisis lineage was stimulated, 
accompanied with a stimulation of G-CSF release (45). In brief, the broad role of IL-
17 extends from its potential in expanding myeloid progenitors, to the initiation of the 
proliferation of mature neutrophils, and also stimulates the secretion of other 
hematopoietic-associated cytokines (46). Additionally to their active or permissive 
role in cell fate commitment, some cytokines hold the ability to induce lineage re-
programming, as it is observed for IL-2: experiments with IL-2Rβ-expressing CLPs in 
culture with medium containing IL-2 induced formation of GM colonies (47); similarly, 
also GM-CSFR expression in CLPs can dictate lineage reprograming, since 
stimulation with GM-CSF is observed to convert CLPs into myeloid cells (48). 
Other cytokines appear to have an active function in the context of 
hematopoiesis. Genes encoding GM-CSF, G-CSF, or erythropoietin (EPO) 
evidenced a reduction in progenitor and mature myeloid cells, without a complete 
loss of the lineage (49). Indeed, in mice deficient for G-CSF, although peripheral 
blood neutrophils were considerably decreased, these cells were still present in the 
blood and BM (50), which indicates that G-CSF does not solely support neutrophil 
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production. Similarly, homozygous mice for a disrupted GM-CSF gene, showed that 
hematopoiesis did not suffer any major perturbation, with maintenance of normal 
levels of mature hematopoietic cells and their precursors in the blood, BM and spleen 
(51). Hong Wu et al. studied the role of EPO in the context of erythropoiesis, showing 
that in fact neither EPO, nor EPOR are required for erythroid lineage commitment of 
progenitors (52). Other studies report that indeed G-CSF, GM-CSF and EPO are 
important for hematopoietic cell function, but their absence is not detrimental to 
lineage commitment or differentiation (53, 54). 
Apart from the meticulously studied cytokines cited above, others exhibit a role 
during the hematopoietic process. Of those, IL-6, IL-7, IL-15 and thrombopoietin 
stand out (42).  
Importantly, the levels of cytokines vary during the life-time of an individual, for 
example during infection. Additionally, genetic mutations in cytokine or cytokine 
signaling pathways deregulate the cytokine response of a given cell. All this might 
impact the regulation of hematopoiesis, eventually leading to disease. 
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2.3. Deregulation of Hematopoiesis 
 
Hematological cancers represent deregulations during the hematopoietic 
process, starting mainly in the BM, and affecting the production and function of blood 
cells (55). The hematological malignancies are diverse, presenting various 
categories of leukemia, lymphoma and myeloma (56). The cause for these blood 
cancers – as for the majority of solid neoplasms – is associated with errors of the 
DNA repair mechanism, resulting in spontaneous mutations (57). Nevertheless, 
cancers can be also caused by microbial agents, such as Epstein-Barr virus, or T-cell 
lymphocytotropic virus (58).  
Myeloproliferative neoplasms (MPNs) are a group of hematologic diseases 
defined by an HSC-derived expansion of one or more myeloid cell lineages. 
According to the World Health Organization (WHO), MPNs are classified as: chronic 
myelogenous leukemia (CML), chronic neutrophilic leukemia, chronic eosinophilic 
leukemia, essential thrombocythemia (ET), mastocytosis, polycythemia vera (PV) 
and primary myelofibrosis (PMF) (59). Of these seven pathologies, three have been 
characterized as Philadelphia-chromosome-negative classic MPNs (60): PV, PMF 
and ET. In brief, patients with PV have an expanded erythroid lineage, consequently 
having a proneness to thrombosis, strokes, and hemorrhages (61). Individuals with 
PMF present a progressive marrow fibrosis, non-specific multi-lineage hematopoietic 
expansions, with occurrence of extramedullary hematopoiesis. PMF is the MPNs 
associated with worst patient outcome (62). ET is defined by proliferation of 
megakaryocytes and platelets in the BM and peripheral blood, leading to an increase 
incidence of thrombosis and bleeding (61). MPNs are of particular interest for this 
thesis, as the studied animal model presents several characteristics resembling 
MPNs, as discussed later on (section 2.6). 
Genetic screenings unveiled the mutational landscape associated with 
several hematological neoplasms; as for instance, the FIP1L1-PDGFRA gene fusion 
in chronic eosinophilic leukemia; or BCR-ABL fusion gene with increased ABL 
tyrosine kinase activity in CML (63). Studies performed in the last decade showed 
that for the classic MPNs, the most relevant mutation to disease development is 
Janus kinase (JAK)2V617F mutation (64). This mutation is responsible for 
constitutively activate the JAK/Signal Transducer and Activator of Transcription 
(STAT) signaling pathway. An incidence of 97% of this mutation in PV and more than 
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50% for patients with ET and PMF was determined (60). Nonetheless, these 
percentages also indicate the possibility of other genetic factors and pathways being 
involved in the development of MPNs (61). In fact, more genetic mutations have then 
been associated with the disease, but the majority of the involved genes actually 
contribute to the epigenetic regulation of JAK2, thus affecting once more this 
pathway (65). For instance, mutations in Ten-Eleven-Translocation2 (TET2) – 
required for DNA hydyroxymethylation – affect mostly HSCs and progenitors and are 
found in approximately 14% of MPN; RUNX1 mutations have been associated with 
the transformation of MPN to Acute Myeloid Leukemia (AML), contributing to the 
severity of the hematological disorder (66). 
The importance of the JAK-STAT pathway in MPNs is reflected on the fact 
that the majority of target therapies available are classified as single-agent JAK 
inhibitors or combination of drugs with JAK-inhibitors (67). Ruxolitinib (Rx) is a JAK 
inhibitor agent FDA and EMA approved, and most prescribed drug to treat MPNs, 
associated with symptom improvement and reduction of the risk of death (68). Other 
JAK2 inhibitors are currently under clinical trials, nonetheless, due to the importance 
of this signaling pathway to a plethora of organism functions, several have been 
discontinued own to high toxicity (69). 
In addition to alterations on the JAK-STAT signaling, as stated above, other 
molecular pathways have been studied. Of relevance is the phosphoinositide 3-
kinase (PI3K) pathway. Aberrant signaling through PI3K pathway has already been 
extensively associated with many cancers, due to its role in cell growth and survival 
(70). Unveiling the association of PI3K with hematologic conditions allowed the 
discovery of several genetic mutations associated with increased risk of disease or 
decreased survival times (71). For instance, the constitutive activation of AKT and 
FOXO1 has been linked to a shorter survival rate of AML patients (72). Abnormal 
genetic programs leading to PI3K hyperactivation have been also observed in 
chronic myelogenous leukemia, acute lymphoblastic leukemia and non-hodgkin’s 
lymphoma (66). In MPNs, BM samples from patients showed an increased 
phosphorylation of AKT, which is indicative of the activation of PI3K pathway (73). 
Owing to the numerous reports on PI3K aberrant activation in hematologic 
conditions, a large number of inhibitors have been developed (74); nevertheless, 
currently there are no FDA-approved PI3K inhibitors for the treatment of MPNs.  
To better understand the complexity of MPNs, and find possible therapeutic 
molecules, several animal models have been exploited. The majority of the mouse 
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models developed recapitulated the genetic background of MPNs. This is the case 
for retroviral transduction of BCR-ABL into murine BM cells; or of transgenic models 
to alter the expression level of a gene of interest, in an inductive or constitutive 
manner (75). Lacout et al. investigated the contribution of the JAK2 V617F mutation 
on MPNs using adoptive transfer of BM cells transduced with retrovirus expressing 
the mutation; the authors extensively studied the mice over-time and observed the 
development of features that mimic human PV (76). Aiming further, an interesting 
study by Tiedt et al. showed that the ration of mutant to wild-type JAK2 is able to 
alter the pathology of the MPN; the authors used an inducible Cre-loxP transgenic 
model, observing that induction of the mutation lower than the endogenous JAK2 
orchestrate ET, whereas a higher ratio leads to PV (77). Apart from these mouse 
models for the direct study of MPNs, other animal models arose from the 
investigation of molecules not before associated with hematopoiesis. Mullenders et 
al. produced shRNA mouse model targeting molecules of the cohesin complex; they 
found that knockdown mice develop MPN, with occurrence of extramedullary 
hematopoiesis (78). Through the development of elegant animal models it is possible 
to decipher the molecules involved in the establishment and progression of MPNs, 
and additionally find therapeutic measures to alleviate disease symptoms.	
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2.4. Hematopoietic Senescence 
 
The aging process of an organism occurs with the concomitant aging of its 
systems. Particularly, during aging the immune system starts to show a reduced 
capacity to respond to infectious agents, dysfunctional host cells, or in some cases 
higher incidence of cancers, such as MPNs (79). An aged immune system is 
characterized by a defective hematopoiesis, leading to deteriorations on the 
frequency and/or function of the blood cells produced. Thus the effects of 
immunesenescence are observed both in precursors and mature cells (80). Despite 
the notable evidences of alterations that immune cells undergo with aging, the 
process of immunosenescence is yet not fully understood, raising innumerous 
hypotheses.  
Prevailing studies place the top of the hematopoietic tree – HSCs – as the 
starting point of the immunesenesce process (81). With age HSCs present particular 
characteristic changes. In an adult, HSCs are a population of low frequency, but both 
in aged mice and humans, a two- to tenfold increase in HSCs was found (82). With 
aging, the recruitment and mobilization of HSCs from the BM to the blood stream 
increases, hence higher percentages of HSCs in circulation are also observed (83). 
However, this expanded population appears to be functional defective, as studies 
show a reduced regenerative potential (84). Consequently, this dysfunction of HSCs 
results in reduced capacity to fully produce competent progenitors of myeloid and 
lymphoid lineages. In fact, aged HSCs present a skewed differentiation capacity 
towards myeloproliferation, with concomitant decreases along the lymphoid lineage 
(81), but with loss of functional competence. Moreover, As for T cells, thymus 
involution is a well-described phenomenon that accompanies aging, resulting in the 
defective generation of naïve T cells, thus decreasing the diversity in the T cell 
repertoire (85). As inferred before, in the BM of elderly people, an increased number 
of myeloid precursors cells is observed: nonetheless, these appear to develop into 
defective mature cells, as it is reported that both macrophages and neutrophils have 
reduced oxidative burst and phagocytic capacity (86).  
Moreover, in individuals of advanced age a state of “inflamm-aging” is also 
detected, where elevated levels of soluble inflammatory immune mediators, such as 
IL-6, Tumor Necrosis Factor (TNF) and IL-1β are reported (87). It is believed that 
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these factors contribute for the progression of age-related inflammatory and 
neurodegenerative disorders (87). 
The alterations impose by aging on hematopoiesis are illustrated in Figure 2. 
 
 
 
 
 
The immunosenescence features cited above justify the susceptibility of aged 
individuals to develop diseases of hematologic nature (88). Indeed, the incidence for 
hematological neoplasms of myeloid nature increases greatly with age (89), being 
Figure 2. Alterations imposed by aging in hematopoiesis. Aging of the hematopoietic process is 
reflected on the expansion of HSCs, shift towards myelopoiesis, and loss of functional competence 
of the mature immune cells. The blue scheme represents a young and healthy hematopoiesis, 
where HSCs display physiological potential for differentiation and self-renewal, giving rise to fully 
competent blood cells of lymphoid and myeloid origin. The grey scheme shows an aged 
hematopoiesis, with HSCs having an abnormal self-renewing capacity and skewed differentiation to 
myelopoiesis, generating mature cells functionally compromised. 
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the majority of patients with blood cancers older than 50 years. Besides the 
increased prevalence, older patients are also much more difficult to cure. Data show 
that for patients older than 65 years, the 5-year survival rate for lymphoma is about 
50% and for myeloma is 20% (56).	
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2.5. Interleukin-10: a Crucial Immune Regulator 
 
IL-10 was firstly described as cytokine synthesis inhibitory factor (CSFI), as it 
was indicated as a product of T-helper 2 (Th2) cells that inhibited proliferation and 
effector function of T-helper 1 (Th1) cells (90). IL-10 was readily identified as an 
inhibitor not only of IFN-γ synthesis by Th1 cells, but also of other known 
inflammatory cytokines, such as IL-2, IL-3, and TNF. Subsequently, other interesting 
observations were made. Malefyt et al. studied the production of IL-10 by monocytes 
upon LPS stimulation, demonstrating that its production occurs later when compared 
to other cytokines and that IL-10 reduces the expression of class II major 
histocompatibility complex (MHCII) (91). Other studies emerged where the inhibitory 
role of IL-10 on immune cells hampering cytokine secretion, NO production and MHC 
expression was reported (92, 93). All these results expose the regulatory role of IL-
10 in controlling immune cell functions. IL-10 is now seen as a critical anti-
inflammatory cytokine, playing an important part in establishing tissue integrity 
homeostasis, by restraining inflammatory responses, thus preventing collateral 
damage during the immune response (94). 
 
 
2.5.1. IL-10 and the IL-10 Receptor 
 
IL-10 acts by binding to its surface heterodimeric membrane receptor 
composed of a α and a β chain: the IL-10 receptor (IL-10R) (95). The ligand-binding 
subunit is the IL-10Rα; it is expressed in hematopoietic cells, but with variable levels 
of expression (96).  
The interaction between the protein IL-10 and its receptor leads to signal 
transduction pathways, via the JAK/STAT system (97). Upon IL-10 binding, the 
interaction between IL-10/IL-10Rα adopts conformational changes in order to allow 
association with IL-10Rβ. The IL-10Rβ is not a major supporter for the IL-10 binding, 
instead its main function is to recruit JAK into the signaling complex (98). JAK1 and 
Tyrosine Kinase 2 (Tyk2) are then activated promoting the phosphorylation of the IL-
10Rα chain on two tyrosine residues, causing the activation of transcription factors of 
the STAT family (99). Of most importance, STAT3 is essential for IL-10 signaling; 
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studies claim the exclusivity of STAT3 in signaling the anti-inflammatory effects of IL-
10 (100). Nevertheless, as these conclusions were not drawn for all cells of 
hematopoietic origin, the involvement of more proteins of the STAT family is 
possible. In support of this, a study found that JAK2 inhibitors might be effective in 
treating diffuse large B-cell lymphoma, since the lymphoma cells present a 
constitutive activation of STAT3, due to signaling via JAK2 (101). 
Recently, another signaling pathway for IL-10 responsiveness was unveiled: 
the PI3K-AKT-GSK3 pathway (102).  The PI3K-AKT-GSK3 pathway is associated 
with several cellular functions, including proliferation, differentiation, metabolism, 
growth, and survival (103). Jihong Shi and colleagues propose that the anti-fibrotic 
potential of IL-10 on fibroblasts is mediated via synergetic activation of PI3K-AKT 
and STAT3 (104). In another study, T. T. Antoniv and L. B. Ivashkiv explored the role 
of PI3K signaling in response to IL-10; their findings on human macrophages 
stimulated with lipopolysaccharide show that PI3K was able to increase IL-10-
mediated inhibition of induced expression of IL-1, IL-8 and cyclo-oxygenase-2 (102). 
Gunzl et al. used a model for constitutively active PI3K in macrophages, and 
observed that cells adopted a strong anti-inflammatory profile via up-regulation of IL-
10 (105). These studies establish and accentuate the relevance of PI3K signaling 
cascade on the response to IL-10 and IL-10 action. 
Besides its clear immunologic role in cytokine signaling, STAT3 has been 
also associated with cancer, since many solid tumors appear to express excessive 
levels of STAT3 (99). Kortylewski et al. found that inhibition of STAT3 in tumor-
bearing mice improves the immune surveillance system, contributing for the inhibition 
of tumor growth and metastasis (101). These observations made for STAT3 are in 
agreement with the puzzling role of IL-10 in cancer biology, as mice and humans with 
deficits in IL-10 signaling appear to develop tumors more easily and rapidly (106). 
Indeed, IL-10 has been associated with the stimulation of cytotoxicity of tumor-
resident CD8+ T cells, being observed a decrease of CD8+ T cells in tumors 
developed in IL-10-/- mice (106). However, given the major role of IL-10 as an anti-
inflammatory and immunosuppressive cytokine, IL-10 is found to be produced by 
some tumor cells, such as lung cancer, melanoma or lymphoma, in order to induce 
the down-regulation of major histocompatibility complex class II expression in antigen 
presenting cells (107). In all, IL-10 appears to have a controversial role in cancer 
immunology, supporting the need for a fine balance of IL-10 anti-inflammatory role. 
Moreover, IL-10 and IL-10 signaling are critical in the gut homeostasis, with mice 
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lacking IL-10 or the IL-10R developing spontaneous colitis (108). Therefore, failing of 
the IL-10-IL-10R system has detrimental and potentially life threatening 
consequences. 
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2.5.2. IL-10 and Hematopoiesis 
 
The importance of IL-10 to immune homeostasis, as a potent anti-
inflammatory cytokine and regulator of inflammation, is undeniable (94). A possible 
role for this cytokine in hematopoiesis remains unknown, but several pieces of 
evidence hint to it. Indeed, LSKs express the surface receptor for IL-10 (109), 
attesting their ability to respond to IL-10. Additionally, HSCs stimulation with IL-10 
enhanced their self-renewal potential (110). The authors took advantage of an IL-10 
deficient mouse model and ex vivo cultures, observing a decrease of progenitor 
hematopoietic populations in the BM of IL-10-/- mice; an enhanced HSC regeneration 
in stromal cultures that produce IL-10; and lastly, the induction of HSC self-renewal 
in purified LSK cultures stimulated with exogenous IL-10 (110). Based on these 
observations, the authors raised the possibility of IL-10 as a cytokine bridging the 
immune and hematopoietic systems.  Another ex vivo study showed a pronounced 
augmentation of myeloid progenitor cells when CD34+ cells cultured with a standard 
cocktail for cell survival were supplemented with recombinant IL-10 (111). However, 
other lineage-associated cytokines were present in the cocktail used as culture 
medium, being the possible effect of IL-10 on lineage-commitment possibly masked. 
Oehler et al. studied the effect of IL-10 on spontaneous hematopoietic colony 
formation in normal human peripheral blood mononuclear cells (PBMCs). Their 
findings place IL-10 as a regulator of hematopoiesis by mediating the release of GM-
CSF by accessory cells (112); additionally, they conclude that IL-10 suppresses 
spontaneous myeloid colony formation by PBMCs, and that this suppressive 
potential is restored upon the addition of GM-CSF (112). Both studies seem to be 
contradictory, but the variability of the results might be due to poor and obsolete cell 
isolation techniques, which can cause culture contamination with cells and/or 
molecules of relevance to hematopoiesis. Other reports evaluating the role of 
cytokines in hematopoiesis have positioned IL-10 as an indirect modulator of this 
process. Fine et al. demonstrated that exposure of cells to IL-10 and IL-7 prompted 
an enhancement in murine pre-B cell colony formation, is spite of IL-10 by itself being 
incapable of any effect on lymphopoiesis (113). In another study, by Rennick et al., 
the differentiation potential of IL-10 was measured by colony-forming assays, having 
the authors concluded that IL-10 solely does not lead to the generation of any mature 
cell; yet when in combination with other cytokines – such as IL3, IL-6, EPO or IL-11 – 
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the growth of megakaryocyte colonies was observed (114). IL-10 was also showed to 
act synergistically with EPO enhancing CFU-Erythroid growth (115). All these reports 
fail to provide a specific role for IL-10 in lineage-commitment, since the presence of 
other cytokines was always required. Moreover, the overall action of IL-10 in lineage 
commitment, how IL-10 might regulate the hematopoietic system, or the molecular 
pathways involved in IL-10-induced HSCs self-renewal remains unknown. 
The in vitro studies performed on the role of IL-10 in hematopoiesis are 
summarized in Figure 3.	
 
 
 
The importance of IL-10 and its clear multidisciplinary promoted the 
progression of in vitro studies to its translation into in vivo clinic studies. Sosman and 
	
Figure 3. In vitro studies establishing a role for IL-10 in hematopoiesis display contradictory 
findings. Several studies suggest the relevance of IL-10 in regulating proliferation and 
differentiation of hematopoietic cells. Nonetheless, a clear role for IL-10 has not been established, 
as a differentiation profile is only obtained in the presence of other cytokines. Additionally, some 
reports present contradictory conclusions. With each finding is associated the correspondent 
reference. Arrows indicate enhancement (é) or inhibition (ê) of a given process.	
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his team conducted a randomized double-blinded and placebo-controlled clinical trial 
to assess the ability of IL-10 to treat thrombocytopenia. To do so, they administered 
recombinant IL-10 in 12 healthy subjects. A significant decrease on platelet 
production was reported, independent of thrombopoietin (TPO) effects, since the 
levels of TPO in the serum of the patients did not decrease (116). Additionally, the 
authors suggest that IL-10 is an appellative candidate for the treatment of 
myeloproliferative conditions, such as PV, where an overproduction of progenitor 
cells is observed (116). Besides being quoted as a therapeutic molecule for 
myeloproliferative diseases, IL-10 was also studied in the context of aplastic anemia: 
Asano et al. administered recombinant IL-10 to seven patients with aplastic anemia, 
reporting a twofold increase of CFU-Erythroid formation in the presence of 10ng/mL 
of IL-10 in two of the seven cases examined (117). In spite of the unsatisfactory 
results, this was the first clinical study where the potential therapeutic effect of IL-10 
on aplastic anemia was investigated. However, the small number of experimental 
subjects restrains the applicability of the results.  
In conclusion, all previous studies assign a possible role for IL-10 during the 
hematopoietic process, observing differences in cell fate commitment; yet they all 
failed to specifically characterize this role, or to identify possible molecular pathways 
for IL-10 action. 
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2.6. The pMT-10 Mouse Model 
 
The mouse model explored during this thesis was the pMT-10, an animal 
model generated by Drs. P Vieira and AG Castro. The pMT-10 mice were generated 
on a C57BL/6 background and are a model for zinc-inducible production of IL-10. In 
brief, the mouse IL-10 cDNA was cloned into a p169ZT vector, which carries a sheep 
metallothioneine (MT) Ia promoter (118). The resulting vector – pMT-IL10 – was 
injected in C57BL/6 eggs and transgenic founders were identified by PCR using 
primers for the IL-10 sequence and MT promoter. Upon administration of zinc, the 
pMT-10 mice display overexpression of IL-10 within 2 days after induction.  
Considering the controversial data on the impact of IL-10 on hematopoiesis, 
its key function in the immune system and the fact that IL-10 is produced during the 
immune response, with many cells responding to it, we set on the study of IL-10 in 
hematopoiesis. For this, pMT10 mouse model is being studied in our laboratory. 
Unpublished data by Ana Cardoso et al. reveals deeper insights to the action of IL-10 
on the hematopoietic process. The study revealed that an overexpression of IL-10 
affects the hematopoietic tree resulting in clear alterations in various hematological 
parameters, compatible with myeloproliferation. Mice overexpressing IL-10 have 
increased numbers of myeloid cells, with decrease on erythrocytes, platelets and B 
cells, which denotes the imprinted tendency for myeloid lineage commitment. 
Furthermore, splenic alterations were also observed, namely marked splenomegaly, 
histological disorganization, and extramedullary hematopoiesis. Finally, preliminar 
experiments show that IL-10 overexpression led to the premature death of the 
animals. The overall characteristics observed in pMT-10 mice over-expressing IL-10 
mimic those observed in other mouse models and in patients of MPNs.  
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2.7. Aims 
 
As mentioned before, previous work done at our lab established that IL-10 
contributes to a deregulation of the hematopoietic process. Since the molecular 
pathways triggered by IL-10 and the cause of death of pMT-10 mice over-expressing 
IL-10 remain to be studied, this work aimed to: 
I. Establish a timeline of events between the BM and spleen, for the 
action of IL-10 in promoting myeloproliferation.  
II. Understanding the signaling cascades that might be involved and 
their significance for clinical purposes. 
III. Decipher the possible role of IL-10 during hematopoietic senescence, 
and the cause of death upon IL-10 overexpression. 
 
	
FCUP 
IL-10 over-expression drives myelopoiesis and premature aging  
25 
	
	
3. Methods and Materials 
 
3.1. Animal Model 
 
Throughout this project, induced pMT-10, non-induced pMT-10 and C57BL/6 
mice were used, with ages between 7 and 10 weeks old. Mice were housed at a 
conventional animal facility, with controlled temperature and humidity, and given food 
and water ad libitum. All mice procedures were performed in accordance with the 
general guidelines for animal welfare and ethic animal treatment: European union 
directive 11686/609/EEC and previously approved by the national authority “Direção 
Geral de Alimentação Veterinária”. 
 
3.2. IL-10 Induction in pMT-10 mice 
 
IL-10 overexpression was induced via administration of zinc sulfate heptahydrate 
(Sigma-Aldrich, USA). A solution of 50nM zinc with 2% sucrose was prepared in the 
drinking water and was deliver to the mice ad libitum, during the experimental period. 
The zinc activates the MT promoter, and within 2 days IL-10 reaches its maximum 
serum expression of 20ng/mL. 
 
3.3. Buparlisib and Ruxolitinib Administration 
 
Buparlisib (NVP-BKM120, Novartis, Basel, Switzerland) – a PI3K inhibitor – and 
Ruxolitinib (NVP-CCA0022, Novartis, Basel, Switzerland) – a JAK1/JAK2 inhibitor – 
were used to evaluate the signaling pathways activated during IL-10 overexpression. 
The administration of Buparlisib (Bp) and Ruxolitinib (Rx) was performed by oral 
gavage, once daily, during the experimental period. Bp and Rx concentration was 
determined based on previous reports using the mice as animal model. The inhibitors 
were freshly prepared, every two days, in methylcellulose solution. The 
methylcellulose solution alone was used on the control groups. 
 
 
	
FCUP 
IL-10 over-expression drives myelopoiesis and premature aging  
26 
	
	
3.4. BM and Spleen Cell Suspensions 
 
Mice were humanely euthanized by CO2 inhalation. Blood was collected by 
heart puncture. Mice were washed with 70% ethanol and a cut was made in the fur, 
near the abdominal region, with a scalpel. The fur was removed to expose the 
forelimbs and the abdominal cavity. Femurs, tibias and spleens were recovered and 
conserved on complete medium HBSS (Hank’s Based Salt Solution, Gibco) 
supplemented with 10% Fetal bovine serum (FBS). BM cells were harvested from 
femurs and tibias with aid of 26G needle and syringe, by flushing with HBSS 
complete medium. The spleens were mechanically disrupted, by mashing the tissue 
with a 40um cell strainer, in a recipient containing HBSS complete medium. Cell 
suspensions were then centrifuged at 1300rpm for 7 minutes at 4ºC. Depending on 
the experiment aim, the erythrocytes were lysed using erythrocyte lysis buffer (0.15M 
NH4Cl, 10mM KHCO3, 0.1mM Na2EDTA in dH2O) incubated for 5 minutes at room 
temperature; or ressuspended in the HBSS complete medium, when the exclusion of 
erythrocytes was not required. Following the lysis of erythrocytes, cells were washed 
by adding complete medium and centrifuging at 1300rpm for 7 minutes, at 4ºC. After, 
cells suspensions were ressuspended in fresh media for posterior analysis. Total 
numbers of cells were determined using an automatic cell counter (Countess, 
Invitrogen, USA). 
 
3.5. Flow Cytometry 
 
Cells from BM and spleen were stained for hematopoietic progenitors and 
mature subsets. To enrich the hematopoietic progenitors subset, first, a depletion of 
mature populations was performed. A cocktail for the mature subsets was prepared 
using anti-CD3, anti-CD4, anti-CD8, anti-CD11c, anti-CD11b, anti-CD19, B220, anti-
NK1.1, anti-GR1 and anti-TER119, all in biotin. BM and Spleen cells were incubated 
with the biotin-antibody cocktail for 20 minutes at 4ºC, and washed twice with 
complete medium by centrifuging at 1300rpm for 7 minutes. Cell suspensions were 
then incubated with Anti-Biotin MicroBeads (MACS, Miltenyi Biotec, Germany) for 15-
20 minutes, at 4ºC. Proceeding a final washing step, cells were ready to magnetic 
separations with LS Columns (MACS, Miltenyi Biotec, Germany). Briefly, columns 
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were carefully placed in the magnetic field of the MACS Separator. All columns were 
pre-washed with complete medium for higher recover. Cells are distributed along the 
columns; cells that pass through, without getting attached to the magnetic field, are 
the unlabeled cells, and represent the enriched lineage negative population, the 
hematopoietic progenitors. After collecting the negative cell fraction, a final washing 
step washing step was done by centrifuging for 7 minutes at 1300 rpm. Cells were 
then counted with an automatic cell counter (Countess, Invitrogen, USA), and stained 
with progenitor markers, namely: anti-FcgR PE; anti-CD34 APC; anti-cKit APC_Cy7 
and anti-SCA-1 FITC, for 20 minutes at 4ºC. Streptavidin (SAV) was also used to 
verify the sample purity. 
The mature populations were assessed by directly incubating BM and spleen 
cells with anti-CD11b PE; anti-Ly6C PBlue; anti-Siglec-F APC; anti-CD11c PE_Cy7 
and anti-Ly6G APC_Cy7, for 20 minutes at 4ºC. 
Stained cells were acquired and analyzed either with LSRII or FACSCanto II 
flow cytometer (BD Bioscience, Franklin Lakes, NJ, USA). Data were analyzed in 
FlowJo software (Tree Star, Ashland, CA, USA), using the gating strategies 
presented in Figure 4. 
 
	
Figure 4. Flow cytometry gating strategy to identify LSKs, and progenitor populations CMPs, 
GMPs and MEPs. Shown are representative dot plots indicating the gating strategy to identify the 
cellular populations of control pMT-10 (top figure) and induced pMT-10 (bottom figure), firstly 
isolating single cells, followed by the lineage negative cells, and finally the LSKs and myeloid 
progenitors. The antibodies used are as indicated in the Materials and Methods. The numbers 
represent the % of cells within each population.	
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3.6. Colorimetric Staining for Tissue Characterization 
 
3.6.1.  Sample Preparation 
 
To prepare samples for histological analysis, spleen, gut, liver, and skin 
samples were fixated in 10% formalin for 48 hours and then embedded in paraffin 
blocks. Tissue was cut in 5µm slices, deparaffinized and rehydrated for further 
hematoxylin & eosin (H&E), and Perls’ staining for liver sections. 
 
3.6.2.  Hematoxylin & Eosin 
 
For the overall examination of the structure of tissues, it was performed 
Hematoxylin & Eosin staining. Firstly, slides containing the tissue preserved in 
paraffin are deparaffinized and rehydrated as it follows: submersion three times in 
xylene (Fischer Scientific, UK), 10 minutes each; followed by sequential submersion 
in 100% ethanol (EtOH), during 10 minutes, 95% and 80% EtOH for 5 minutes. 
Finally sections are washed in deionized H2O and stained with hematoxylin solution 
(Sigma-Aldrich, MO, USA) during 45 seconds, being then rinsed with deionized 
water. To destain, the sections were rapidly dip in acid ethanol and washed again. 
Samples were immersed in Eosion solution (Sigma-Aldrich, MO, USA) for 30 
seconds. To dehydratate, slides were successively dipped for 5 minutes in 95% and 
100% EtOH, followed by 30 minutes of 15% in xylene.   
 
3.6.3.  Perls Prussian Blue Staining 
 
To evaluate the deposition of iron in the liver, it was performed a Perls 
Prussian Blue Staining. Liver sections previously cut were placed two times in xylol 
(Fischer Scientific, UK), 10 minutes each time. The slides were then treated with 
gradient percentages of EtOH: 10 minutes in 100% EtOH; 5 minutes in 96% EtOH; 5 
minutes in 70% EtOH; 5 minutes 50% EtOH. Afterwards, slides were washed in 
dH2O 3 times, during 5 minutes each time. Freshly prepared Perl’s solution (filtered 
solution of 2% of Potassium hexacyanoferrate (II) trihydrate (Merck) and 2% 
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hydrochloric acid 37% (Sigma-Aldrich, MO, USA) in deionized H2O) was made.  The 
slides were stained with Perl’s solution for 30 minutes, followed by a washing step 
with deionized H2O during 5 minutes. The, slides were stained for 1 minute with 
Neutral Red (Sigma-Aldrich, MO, USA), and washed again with dH2O water. To 
dehydrate, slides were rapidly and successively submersed in 70% EtOH, 96% 
EtOH, 100% EtOH; and 10 minutes in xylol. Finally, slides were mounted in Entellan 
(Sigma-Aldrich, MO, USA). 
 
3.7. Blood Smears 
 
Blood smears were stained with Wright stain solution (Sigma-Aldrich). A drop of 
blood freshly collected from each animal was applied in an extremity of a glass slide 
(Menzel-Glaser, Thermo Scientific). With the aid of other slide, the drop was spread 
along the initial slide, and let to dry. Submersion of samples in Wright solution was 
performed for approximately 15 seconds. After, slides were washed with dH2O. 
 
3.8. Fibroblasts Cell Culture 
 
A primary cell culture of fibroblasts were established by mechanically and 
enzymatically digest ears of adult C57BL/6 mice. After harvesting, the ears were 
washed with PBS, and placed in DMEM:F12 with 0.125mg/mL collagenase IIS 
(Sigma) and 1.25mg/mL collagenase type II (Gibco). The ears were then cut in small 
pieces, with the aid of tweezers and surgical scissors. The specimens were 
incubated for 45 minutes at 37ºC and 5% CO2. Enzymatic digestion was stopped by 
adding DMEM:F12 medium supplemented with 10% FBS, 1% antimycotic antibiotics. 
The cell culture was kept at 37ºC and 5% CO2. Possible tissue lumps were 
removed by washing with PBS 1x and suction needle. The medium was replaced 
every three days. Once adherent fibroblast reached confluence, cells were 
transferred to a 25cm2 flask. 
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3.9. Senescence and proliferation 
 
3.9.1. Cell culture 
 
Fibroblasts were firstly grown on a 24-well plate, onto sterilized glass 
coverslips coated with fibronectin (Sigma-Aldrich, MO, USA), in DMEM:F12 
supplemented with 10% FBS and 1% antibiotic-antimycotic solution. The culture was 
kept in an incubator at 37ºC with 5% CO2. Cells were then stimulated with varying 
doses of recombinant IL-10 (R&D Systems), namely, 10ng/mL and 50ng/mL, during 
different time periods, 24 and 48 hours. Control cells were not stimulated with 
recombinant IL-10. 
 
3.9.2. Senescence-associated β-galactosidase activity 
 
Cells previously cultured on sterilized glass coverslips, were submitted to 
senescence-associated β-galactosidase assay by incubating with 100nM bafilomycin 
A1 (Sigma-Aldrich, MO, USA) for 90 minutes at 37ºC, 5% CO2. Then 33µM of 5-
dodecanoylaminofluorescein di-β-D-galactopyranoside (C12FDG, Sigma-Aldrich, 
MO, USA) was added to the cell culture and cells were again incubated for 90 
minutes. The cells were fixed in freshly prepared 4% paraformaldehyde in PBS for 15 
minutes at room temperature, washed with PBS three times and then permeabilized, 
for 15 minutes at room temperature, in PBS buffer containing 0.1% Triton-X 100. 
After fixation and permeabilization steps, cells were washed in PBS-T (PBS with 
0.05% Tween 20). Slides were washed and counterstained with DAPI (1 µg/mL) 
(Sigma-Aldrich, MO, USA). 
 
3.9.3. Ki67 and p21 staining for proliferation and cell cycle arrest 
 
For immunostaining, cells formerly cultured onto sterilized coverslips, were 
fixed in freshly prepared 2% paraformaldehyde in PBS for 20 minutes at room 
temperature, washed with PBS three times and then permeabilized for 7 minutes at 
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room temperature in PBS buffer containing 0.3% Triton-X 100. Following fixation and 
permeabilization, cells were washed in PBS-T three times, and blocked with a 
solution of 10% FBS in PBS-T for 1 hour at room temperature. Cells were then 
incubated at 4ºC overnight with primary antibodies dilution in 5% FBS in PBS. Later, 
cells were washed in PBS-T three times, and incubated at room temperature for 45 
minutes with secondary antibodies diluted in 5% FBS. Cells were finally washed, 
stained with DAPI for 10 minutes, and the coverslips were mounted on microscope 
slides in an anti-fade solution containing 90% glycerol and 0.5% N-propylgallate. 
Primary antibodies were diluted as follows: mouse anti-p21 (SC-6246, Santa Cruz 
Biotechnology, CA, USA) 1:1000; mouse anti-ki67 (M-19, Santa Cruz Biotechnology, 
CA, USA) 1:1000. Secondary antibodies were diluted as follows: Alexa Fluor 488 and 
568 diluted 1:1500 (Life Technologies CA, USA) and DNA was counterstained with 
DAPI (1µg/mL) (Sigma-Aldrich, MO, USA). 
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4. Results and Discussion 
 
4.1. Molecular Mechanisms Underlying IL-10-induced 
Myeloproliferation 
 
As stated before, pMT-10 mice induced to over-express IL-10 develop a 
phenotype of pronounced myeloproliferation. In the first part of this thesis, we 
focused in obtaining a more detailed picture of the IL-10-induced hematopoietic 
deregulation and of the involved molecular players and signaling cascades. 
 
4.1.1. IL-10-induced Myelopoiesis Occurs in the Bone Marrow 
and Spleen at Different Time Points 
 
The phenotype observed on induced pMT-10 mice affects the overall 
hematopoietic process, with notorious physiologic alterations, such as abnormal 
hematological parameters, with the propensity to a myeloproliferation, the occurrence 
of extramedullarly hematopoiesis, and splenomegaly. Previous and current studies 
performed in our lab placed the BM and the spleen as cardinal organs responding to 
the IL-10-induced overexpression phenotype. Nonetheless, the initial target for the 
action of IL-10 remains unclear. To answer this question a kinetic assay was 
performed. pMT-10 mice were fed with zinc in water for 7, 15 and 30 days. At each 
time point, serum from the blood was collected and cell populations from the BM and 
spleen analyzed by flow cytometry. Non-induced pMT-10 mice were used as control 
groups. Figure 4 shows the gating strategy used to identify the different cellular 
populations under study: LSKs, myeloid progenitors and mature myeloid cells. At day 
7 post-IL-10 induction, a significant increase of LSKs and GMPs in the BM, 
accompanied with decrease in CMPs, is observed remaining at a relatively constant 
level after that time-point (Figure 5). The spleen follows a kinetic pattern similar to 
that of the BM, with a substantial increase in LSKs visible already at day 7. However, 
the populations of GMP and CMP are affected in the spleen at a later phase than in 
the BM. The fact that, in the spleen, the increase of GMPs occurs later, might 
suggest that this population requires a stage of cell migration from the BM, preceding 
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a period of expansion and differentiation in the spleen. This hypothesis is further 
supported by the spleen size assessment shown in Figure 6, since the splenomegaly 
– well evident on day 30 of IL-10 overexpression by a significant increase in spleen 
weight – is not visible on day 7 on IL-10 induction. The striking decrease of CMPs is 
noticeable and somehow surprising, consider the increase of GMPs. A possible 
explanation is that this population is being quickly exhausted owing to the abnormal 
requirement for GMP production. The population of MEPs presented no significant 
alterations when comparing control and zinc-induced pMT-10 (data not shown). 
 
A time-dependent increase in mature cell populations, precisely 
CD11b+Ly6C+Ly6G+ and CD11b+Ly6C+Ly6G-, was also observed in both the BM and 
the spleen (Figure 7). This suggests that the expanded GMP population is likely 
competent in both organs, being able to differentiate into mature myeloid cells. 
Together, the combined increase of progenitors and mature cells most likely 
accounts for the observed splenomegaly. Moreover, the increase of GMP in the 
spleen hints at the occurrence of extramedullary hematopoiesis. 	
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Figure 5. Percentage of LSKs and hematopoietic progenitor cells over time in the bone marrow or 
spleen of control and induced pMT-10 mice. The percentage of LSKs, CMPs and GMPs was 
measured by flow cytometry at days 0, 7, 15 and 30, after zinc-induced IL-10 overexpression. Induced 
pMT-10 mice show an increased percentage of LSKs and GMPs both in BM (left panel) and spleen (right 
panel), with concomitant decrease of CMPs. The data are presented as the mean ± SEM; **** represent 
a p value ≤ 0.0001; *** represent a p value ≤ 0.001; One-way ANOVA test. SEM, standard error of the 
mean. Data are from one representative experiment of 3. 6 animals per group. 
 
	
FCUP 
IL-10 over-expression drives myelopoiesis and premature aging  
35 
	
	
 
 
																															 	
Figure 6. IL-10 overexpression results in splenomegaly. At day 30 post-IL-10 induction, the spleens of 
pMT-10 mice present a significative two-fold increase when compared with non-induced mice. The 
increase of spleen weight is also significative between time points (day 7 and 30), for the induced pMT-10. 
The data are presented as the mean ± SEM; **** represent a p value ≤ 0.0001; *** represent a p value ≤ 
0.001; One-way ANOVA test. SEM, standard error of the mean. Data are from one representative 
experiment of 3. 6 animals per group. 
 
	
Figure 7. Percentage of hematopoietic mature cells over time in the bone marrow or spleen of 
control and induced pMT-10 mice. The percentage of CD11b+Ly6C+Ly6G+ and CD11b+Ly6C+Ly6G- was 
determined by flow cytometry at days 0, 7, 15 and 30, after zinc-induced IL-10 overexpression. Both in BM 
(left panel) and spleen (right panel) is observed an increase of these populations over time. The data are 
presented as the mean ± SEM; **** represent a p value ≤ 0.0001; *** represent a p value ≤ 0.001; ** 
represent p value ≤ 0.01; * represent p value ≤ 0.05. One-way ANOVA test. SEM, standard error of the 
mean. Data are from one representative experiment of 3. 6 animals per group. 
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Another important feature observed in pMT-10 mouse over-expressing IL-10 
is the histological disorganization of the spleen, in which the white and red pulps 
become undefined (A. Cardoso, unpublished data). Surprisingly, this phenotype is 
already evident at day 7 (Figure 8), which might indicate that the cellular population 
orchestrating the splenic disorganization probably belongs to the LSK compartment. 
Within the spleen, under physiological conditions, HSCs locate close to endothelial 
cells in the splenic red pulp. Nonetheless, in induced pMT-10 mice the precise 
localization of the HSCs pool becomes of difficult interpretation. A study from Kiel et 
al. showed that CD150+ HSCs mobilized to the spleen, during EH, are in contact with 
sinusoidal endothelial cells in the red pulp (119); nevertheless, it is still undermined 
whether these HSCs maintain this localization or change it overtime.  
 
 
 
Altogether, our results highlight to a defective hematopoiesis, caused by an 
IL-10-induced stress on the BM, which later leads to extramedullary hematopoiesis 
along with splenomegaly and abnormal myeloproliferation. 
																										 	
Figure 8. Spleen histology of control and induced pMT-10 mice. Figures portray the 
disorganization of the splenic structure, with a scattered white pulp, in zinc-induced pMT-10 mice, 
both at day 7 and day 30 after IL-10 overexpression. Control non-induced pMT-10 mice preserve 
the original architecture of the spleen. Magnification x 4. Represented are the spleens of one mouse 
per group, from a total of 12, in two independent experiments.  	
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Several animal models show alterations that shift hematopoiesis towards 
myelopoiesis, progressively leading to splenomegaly. Notably, these models result 
from abnormal proliferative signals (such as the V617F JAK2 transgenic model) (76), 
apoptotic cascades (such as the Bim deficient animal) (120), deletion of specific 
genes with known contribution during hematopoiesis (as the deletion of AML1 gene 
causes a preleukemia state) (121), or the manipulation of genes involved in cell cycle 
(such as the cohesin knockdown) (78). In a way, the association of proteins linked 
with these cellular processes and the establishment of neoplasms is understandable. 
However, taking into consideration the main role of IL-10 as an anti-inflammatory 
cytokine, it is remarkable that an overexpression of IL-10 would also lead to 
hematologic neoplasms. The next section investigates the molecular mechanisms 
involved in this process. 
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4.1.2. Molecular Mechanisms Underlying IL-10-driven 
Myelopoiesis: Inhibitors for JAK2/STAT and PI3K 
Ameliorate the IL-10-induced Phenotype 
 
The pMT-10 mouse model for induced IL-10 overexpression undoubtedly 
reflects a phenotype for deregulated BM hematopoiesis, with a shift to myelopoiesis. 
To determine the molecular pathways involved remains an outstanding question. 
Among the signaling cascades triggered upon activation of the IL-10R are the JAK-
STAT and PI3K-AKT-GSK3 pathways (99, 102). Of these, the most broadly studied 
is the JAK-STAT cascade, implicated in the majority of the anti-inflammatory 
responses promoted by IL-10. Recent reports have however revealed the 
contribution of PI3K in regulating IL-10 functions. Notably, the activation of IL-10R 
promotes cell survival, by activating PI3K-AKT pathway, which in turn increases the 
activity of anti-apoptotic molecules.  
To assess the involvement of these pathways in orchestrating IL-10-induced 
myeloproliferation, pMT-10 mice were induced to over-express IL-10 for 30 days 
after which they were treated with the JAK2/1 inhibitor ruxolitinib (Rx), the PI3K 
inhibitor buparlisib (Bp) or both for 7 days. The concentration of the drugs used was 
defined by manufacturer guidelines, for animal’s welfare and reduced toxicity. After 
the 7 days of treatment, we evaluated the phenotype of pMT-10 over-expressing IL-
10 at the BM and spleen levels. In what regards the spleen, both inhibitors led to a 
significant reduction on its size, thus proving Rx and Bp efficacy in reverting the 
splenomegaly (Figure 9A and 9B). Furthermore, the histological disorganization, 
characteristic of the IL-10-induced overexpression (Figure 8), was reverted (Figure 
9C), with the spleen of treated animals exhibiting perceptible white and red pulps. 
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Figure 9. Administration of JAK2 and PI3K inhibitors rescued the splenomegaly induced by 
IL-10 and ameliorated the histological disorganization of the spleen. Oral administration of 
JAK2 and PI3K inhibitors for 7 days, after 30 days of induced IL-10 overexpression, recovered the 
splenomegaly as evidenced by the spleen size (A) and weight (B). The structural organization of the 
spleen is also regained (C). (A,B) The data are presented as the mean ± SEM; **** represent a p 
value ≤ 0.0001; ** represent p value ≤ 0.01. One-way ANOVA test. SEM, standard error of the 
mean. Data are from 1 representative experiment of 2. (C) Magnification x 4. Represented are the 
spleens of one mouse per group, from a total of 12, in two independent experiments. 
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The progenitor and mature cellular populations were analyzed in the spleen 
(Figure 10) and bone marrow (Figure 11), to investigate if the blockade of the JAK2 
and/or PI3K pathways would rescue the physiologic levels of these cells. In the 
spleen, the percentage of LSKs was only altered in the presence of Bp, showing an 
appreciable decrease (Figure 10A). However, no significant differences were found 
for the percentages of GMP or CMP populations (Figures 10B and 10C). As for the 
mature cells a significant reduction was only observed for Ly6C+Ly6G+ in animals 
treated with Bp or with both inhibitors (Figure 10E). Thus, the reduction of the 
splenomegaly observed upon Bp treatment (Figures 8A and 8B) is likely due to the 
effect of the inhibitor on LSKs and on mature Ly6C+Ly6G+ cells. However, a reduction 
of splenomegaly upon treatment with Rx is observed (Figures 9A and 9B), despite 
less significant when compared with Bp. This finding is not associated with a 
decrease in the cellular populations analyzed (Figure 10); hereinafter, this 
experiment needs to be repeated or other populations investigated. 
 
					 	
Figure 10. Effect of the administration of JAK2 and PI3K inhibitors on progenitor and mature cells 
of the spleen. The cellular composition of the spleen was determined for the different experimental groups 
by flow cytometry. The PI3K inhibitor Bp displays the most significant results, with decrease of LSKs and 
Ly6C+Ly6G+ when compared to induced pMT-10 mice. Rx administrations appears to not affect the 
induced-pMT-10 phenotype. The data are presented as the mean ± SEM; **** represent a p value ≤ 
0.0001; *** represent a p value ≤ 0.001; * represent p value ≤ 0.05. One-way ANOVA test. SEM, standard 
error of the mean. Data are from 1 representative experiment of 2. 6 animals per group. 
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In what concerns the bone marrow, we observed a significant decrease in the 
LSK population across all treatments (Figure 11A), although the CMP and GMP 
populations remained unaltered (Figures 11B and 11C). As for the mature cells, we 
observed a reversion on the % of Ly6C+Ly6G-, but not of Ly6C+Ly6G+  (Figure 11D 
and 11E) in contrast to what was found in the spleen. It is possible that a prolonged 
treatment would result in a better outcome, and perhaps a fully recovery of the 
hematopoietic cells of the BM, that would lead to cease extramedullary 
hematopoiesis. 
				 	
Figure 11.  Effect of the administration of JAK2 and PI3K inhibitors on progenitor and mature 
cells of the BM. The cellular composition of the bone marrow was determined for the different 
experimental groups by flow cytometry. The PI3K inhibitor Bp, or a combination of both inhibitors, 
display better results, leading to a statistically significant decrease of LSKs and Ly6C+Ly6G- 
populations. The JAK2 inhibitor Rx leads to a reduction of LSKs and Ly6C+Ly6G-, but with less impact 
when compared to Bp. The data are presented as the mean ± SEM; **** represent a p value ≤ 0.0001; 
*** represent a p value ≤ 0.001; ** represent p value ≤ 0.01. One-way ANOVA test. SEM, standard 
error of the mean. Data are from 1 representative experiment of 2. 6 animals per group. 
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Therefore, the phenotype induced by IL-10 overexpression was not fully 
reverted by the tested inhibitors, with the overall best result reported for Bp. 
Importantly, deregulation of the PI3K signaling is associated with the development of 
one third of cancers, including lymphocytic leukemia (122). Interestingly, blocking 
both pathways at the same time did not potentiate the overall action of each single 
inhibitor. Presumably, other signaling cascades or kinases might be implicated. Both 
inhibitors seem to act in the BM and spleen, being the population with the most 
striking differences the LSKs. It is possible that a more prolonged treatment would 
result in a better outcome, and perhaps a fully recovery of the hematopoietic cells of 
the BM.  
Several studies on cancer signaling reported a synergistic link between JAK 
and PI3K pathways (123, 124). With our results we can also hypothesize whether, 
due to the connection between JAK and PI3K, by blocking JAK the most affected 
signaling cascade is in fact PI3K and not STAT. This theory would explain why solely 
Rx is not much effective, nor a combination of the two inhibitors increases 
responsiveness of the cells. 
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4.1.3. PI3K Signaling Cascade: a Key Process Driving IL-10 
Induced Myeloproliferation 
 
Since the previous data supported a greater effect for Bp in rescuing the IL-
10-induced phenotype, we next treated pMT-10 mice with Bp for 7 days, starting at 
the same time of the zinc-induced IL-10 overexpression. The aim was to investigate 
whether PI3K inhibition could prevent IL-10-induced myeloproliferation.  
As shown in Figure 12, blockade of the PI3K pathway attenuated the effect of 
IL-10, as observed by the absence of splenomegaly and spleen weight maintenance. 	
 
A 
	
B 
	
Figure 12. Early inhibition of the PI3K signaling cascade blocks the IL-10 induced phenotype 
in the spleen. Spleen size (A) and weight (B) after 7 days of induced IL-10 overexpression, in the 
absence or presence of PI3K inhibitor Bp. Treated mice show an effective blockade of the 
splenomegaly, when compared to control and induced pMT-10 mice. The data are presented as the 
mean ± SEM; *** represent a p value ≤ 0.001; ** represent p value ≤ 0.01. One-way ANOVA test. 
SEM, standard error of the mean. Data are from 1 representative experiment of 2. 6 animals per 
group. 
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The analysis of the spleen cellular composition upon treatment of pMT10 
mice with Bp showed that all the tested populations, from LSKs to mature cells, 
maintain their normal frequency (Figure 13). The effectiveness of Bp is also evident 
in progenitors and mature cells of the BM (Figure 14). A decrease on the expanded 
LSK population is apparent, but not statistically significant (Figure 14A). However, all 
other tested populations remain within normal percentages, by comparison with the 
non-induced pMT-10 (Figure 14). Of note, GMPs were also rescued, but still show 
differences as compared to the control (Figure 14C).  
    
	
Figure 13. Administration of PI3K inhibitor Bp blocks the IL-10-induced myeloproliferation in 
the spleen. Spleens from the different experimental groups were harvested on day 7 of the 
experiment and the cellular composition determined by flow cytometry. The data are presented as 
the mean ± SEM; **** represent a p value ≤ 0.0001; ** represent p value ≤ 0.01; * represent p value 
≤ 0.05. One-way ANOVA test. SEM, standard error of the mean. Data are from 1 representative 
experiment of 2. 6 animals per group. 
 
	
FCUP 
IL-10 over-expression drives myelopoiesis and premature aging  
45 
	
	
  
 
 
 
In summary, we showed that blockade of JAK2 or PI3K cascades reverted to 
a certain extent the IL-10-induced aberrant myeloproliferation. Moreover, inhibition of 
the PI3K signaling also impaired the phenotype establishment, thus highlighting a 
potential application of Bp in very early stages of disease. A role for IL-10R induced 
PI3K-AKT in myeloid cell fate has been proposed before, by triggering a molecular 
program for inhibition of apoptotic death of myeloid progenitors (125). Therefore, by 
inhibiting PI3K, the anti-apoptotic role of IL-10 may be blocked. Thus, it is possible 
that IL-10 may be acting on LSKs and GMPs, by inducing anti-apoptotic programs, 
leading on the other hand to an exhaustion of CMPs. Also, Flt3 internal tandem 
	
Figure 14. Administration of PI3K inhibitor Bp blocks the IL-10-induced myeloproliferation in 
the BM. Bone marrows from the different experimental groups were harvested on day 7 of the 
experiment and the cellular composition determined by flow cytometry. The data are presented as 
the mean ± SEM; **** represent a p value ≤ 0.0001; *** represent p value ≤ 0.001; ** represent p 
value ≤ 0.01; * represent p value ≤ 0.05. One-way ANOVA test. SEM, standard error of the mean. 
Data are from 1 representative experiment of 2. 6 animals per group. 
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duplications (Flt3-ITD) were found in AML patients, where the constitutive activation 
of AKT, via PI3K, mediated survival, proliferation and leukemic transformation of 
myeloid cells, in vitro and in vivo (126). Thus, PI3K is gaining importance as a 
promoter of myeloid neoplasms, which supports our data for IL-10-induced 
myeloproliferation. These hypotheses remain to be investigated and are subject of 
current studies in our lab. 
Importantly, the potential involvement of JAK2 signaling pathway on the 
phenotype induced by IL-10 should not be disregarded. Inhibition with Rx appears to 
moderately affect the IL-10 overexpression phenotype. A study by Mascarenhas et 
al. explored the role of both JAK/STAT and PI3K pathways in HSCs, during 
embryonic development (127). According to the authors, the JAK pathway has a 
differential proliferative role, when associated with cytokine-mediated expansion, 
since it is required for IL-3 signaling, but not for thrombopoietin signaling. Moreover, 
PI3K inhibition led to a diminished production of hematopoietic progenitors, both in 
the presence and absence of additional cytokines; this effect was associated with an 
increase in pre-apoptotic cells (127). These results on signaling pathways of 
embryonic HSCs support our results on adult HSCs. 
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4.1.4. Clinical Implications and Outstanding Questions 
 
Unpublished data from out laboratory exposed an unexpected role for IL-10 in 
deregulating hematopoiesis. Given the relevance of IL-10 in the immune response 
and the fact that many immune cells produce and respond to IL-10 during infection, 
as well as the therapeutic potential of manipulating IL-10 in immune related 
disorders, fully clarifying the role of this cytokine in hematopoiesis is of major 
importance. The work developed during this thesis aimed at revealing the molecular 
pathways underlying this novel role for IL-10. 
The overall phenotype of the induced pMT-10 mice mimics the phenotype 
observed in other mouse models for MPN. MPNs are a heterogeneous group of 
diseases that is characterized by an increase in non-lymphoid hematopoietic cells in 
the spleen or BM; the classical MPNs are polycythemia vera, essential 
thrombocythemia and myelofibrosis (61). The JAK2V617F mutation – where JAK2 is 
constitutively active – was found to be present in many patients diagnosed with 
MPNs; the discovery of this JAK2 mutation led to the development of several 
therapeutic JAK2 inhibitors (67). Indeed, Rx is used in the clinic, demonstrating the 
ability to alleviate some symptoms of the patients, such as to reduce the 
splenomegaly (68). Nonetheless, administration of Rx does not represent a cure, as 
the hematological alterations persist in the BM of the patients. These same results 
were observed when induced pMT-10 mice were treated with Rx.  
Due to the heterogeneity of MPNs and the crosstalk between JAK-STAT and 
other signaling pathways, other non-JAK2 inhibitors have been used, for instance, 
histone deacetylase inhibitors, and the anti-fibrotic agent pentraxin (61). An 
interesting study by Choong and colleagues reported the administration of combined 
inhibitors to treat MPNs in a mouse model for JAK2V617F mutation (123). The 
authors screened several serine threonine kinase inhibitors, concluding that a more 
efficient treatment was achieved when combining JAK2 inhibitor – Rx in particular – 
with a PI3K inhibitor. It was argued that a better therapeutic approach should be 
accomplished by administering both drugs but at lower doses, since they act 
synergistically. We observed that PI3K inhibition both reverted and prevented the 
deregulated myelopoiesis induced by IL-10. Most notably, this effect occurred at the 
BM and spleen level. Although PI3K inhibitors have proven to be effective in multiple 
solid tumor types, little is described on its effect on MPNs (128). Additionally, in line 
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with previous studies (123, 124), we also show a better outcome when administering 
Rx and Bp rather than Rx alone. Thus, our data highlights the potential of these 
drugs in MPNs, calling for deeper research in this area, specifically, by evaluating the 
role of downstream molecules, since the PI3K pathway itself is associated with a 
plethora of cell functions: metabolism, growth, autophagy, survival. It will also be of 
interest to assess the effectiveness of PI3K inhibitors in other pre-clinical models of 
MPNs. 
Figure 15 summarizes the main conclusions drawn from the administration of 
the inhibitors. 
 
	
Figure 15. Schematic representation of the pathways involved during IL-10 driven 
myeloproliferation. Based on our results, both JAK-STAT and PI3K pathways are involved in IL-
10-induced myeloproliferation. Administration of JAK2 and PI3K pathway inhibitors Rx and Bp 
attenuates the myeloproliferative phenotype, after 30 days of induced IL-10 overexpression. 
However, inhibition of the PI3K cascade might have a more relevant role, as administration of the 
PI3K inhibitor Bp, at early stages of the establishment of the disease, blocked the progression of the 
phenotype into a myeloproliferation.	
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4.2. Long-term Effect of IL-10 Overexpression  
 
4.2.1. Sustained IL-10 Overexpression Leads to Premature Death 
 	The induction of IL-10 overexpression on pMT-10 mice triggers numerous 
cellular alterations that affect the hematopoietic process, inducing a pronounced 
myeloproliferation. Following these observations, we sustained IL-10 over-expession 
overtime and found that it culminated with the premature death of the mice. Figure 16 
represents the survival curve of induced and control pMT-10. Of note, BL6 animals 
fed with zinc for the entire period of the experiment (up to day 150) did not die 
prematurely. Hence the zinc dosage is not toxic. Moreover, induced pMT-10 
presented signs of lordokyphosis and lethargy. 
																					 	
Figure 16. IL-10 overexpression leads reduces the mice life span. Mice were maintained in a 
normal diet or fed with zinc-enriched water and monitored over-time. Control pMT-10 and BL6 
animals fed or not with zinc presented a normal survival. pMT-10 mice fed with zinc showed signs of 
poor health condition and were humanely sacrificed at different times from day 50 onwards. Data 
are from 1 representative experiment of 2. 6 animals per group.	
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4.2.2. Sustained IL-10 Overexpression Leads to Blood Alterations 
Compatible with CMML 
 
To determine the possible cause of death of the IL-10 over-expressing 
animals, several parameters were measured at an experimental endpoint determined 
by an evaluation of the animals’ health condition. 
Firstly, we hypothesized that prolonged IL-10 overexpression may be driving 
the development of AML, as the progression of MPNs to AML in human patients is 
among the most common causes of death (129). To address this hypothesis, blood 
smears from IL-10 over-expressing animals and controls were obtained and stained 
with Wright-Giemsa (Figure 17). The first-line diagnostic procedure when a patient is 
suspected of AML is to obtain BM aspirates or blood to analyze cell morphology. As 
a routine procedure, blood and BM smears are stained with Wright-Giemsa, to check 
for blasts; for an AML diagnosis a count of 20% or more blasts is required (130). 
According to our observations, the blasts found were not enough to assuredly identify 
the phenotype as AML.  
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 Next, hemograms of pMT-10 over-expressing or not IL-10 were obtained, as 
hemograms allow a more rigorous diagnosis of certain blood disorders. Figure 18 
represents the comparative counts for red blood cells, white blood cells, platelets, the 
hematocrit, hemoglobin, mean cell volume (MCV), and leukocytes count. As 
observed, induced pMT-10 mice presented significantly lower values of red blood 
cells (18A), platelets (18E) and hemoglobin (18C) when compared with controls. 
Moreover, the induced pMT-10 mice showed values close to the borderline reference 
ones, indicating that the mice were anemic. This was further supported by the 
significant decrease on the hematocrit percentage. The anemia was additionally 
confirmed with Perls staining of liver sections, as it is visible the deposition of iron 
(Figure 19). The MCV of the induced pMT-10 was elevated when compared to that of 
control mice (Figure 18D). An assessment of the MCV can elucidate about the 
typology of anemia; in this context, the increased MCV might imply an aplastic 
anemia, hemolytic anemia or a myelodysplastic syndrome. Another interesting result 
		Figure 17. Peripheral blood smears from induced pMT-10 mice display monocytic blasts. 
Wright-Giemsa stains from peripheral blood smears of control or induced pMT-10 mice. Monocytic 
blasts are indicated by the black arrows. The blood cells of control pMT-10 mice present a normal 
morphology. Represented are the smears of two mice per group, from a total of 12, in two 
independent experiments. 
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is the decrease in platelets count (Figure 18E), also known as thrombocytopenia. 
This result is also compatible with a myelodysplastic syndrome or with the 
development of leukemia. The number of neutrophils and eosinophils appeared to be 
higher in induced pMT-10 than in the control (Figures 18H and I), whereas the 
number of basophils did not change upon IL-10 overexpression (Figure 18J). Since 
AML is defined by neutropenia, these results exclude a typical AML as possible 
cause of death of the induced pMT-10.	
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F Figure 18. IL-10 overexpression for 60 days induced significant hemogram alterations. The hemograms of 
control and induced pMT-10 mice were obtained 60 days after zinc administration. Graphics of the counts for red 
blood cells (A), hematocrit percentage (B), hemoglobin (C), mean cell volume (D), platelets (E), white blood cells (F), 
monocytes (G), neutrophils (H), eosinophils (I) and basophils (J). The grey area represents the physiological values, 
also depicted below the graphics as reference values. The data are presented as the mean ± SEM; *** represent p 
value ≤ 0.001; ** represent p value ≤ 0.01; * represent p value ≤ 0.05. One-way ANOVA test. SEM, standard error of 
the mean. Data are from 1 representative experiment of 2. 
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A possible alternative is the development of chronic myelomonocytic 
leukemia (CMML) in response to IL-10. This hypothesis is compatible with the 
accumulation of monocytes, increase proliferation of the granulocytic lineage and the 
evidence of myelodysplasia observed upon overexpression of IL-10 in pMT-10. 
Indeed, flow cytometry analysis of the spleen and BM of induced pMT-10 (Figures 5 
and 7) and the blood analysis (Figure 18) show an expansion of the granulocytic cell 
lineage (131). According to WHO classifications, the main clinical difference between 
CMML and other MPNs is the defective hematopoiesis that leads to more persistent 
anemias and thrombocytopenia, both phenomena also observed in induced pMT-10 
mice (60). Furthermore, patients with CMML also display blasts on BM and blood 
smears, usually below 20%, which is in line with the observations of the blood of 
pMT-10 + Zinc (Figure 17). 
 
CMML is a rare disease that affects mostly people older than 60 year, being 
age a risk factor (132). In human patients, the prognosis of CMML is poor, since 
there is no curative treatment, only therapeutic measures in order to ameliorate the 
quality of life of the patients, such as drugs to control the myeloproliferation, to repair 
the anemia and delay disease progression (133). Thus, further investigating the 
pMT-10 mouse model as a possible CMML animal model may be of interest, 
	
Figure 19. Prolonged IL-10 overexpression induces the accumulation of iron on the liver of 
pMT-10 mice. Perl’s staining of liver sections of induced-pMT-10 mice 60 days after IL-10 induction. 
The pursian blue stain indicates deposition of iron, which corroborates with the anemic state of the 
mice. Magnification on the right x4; magnification on the left x10. Represented are the spleen of one 
mouse per group, from a total of 12, in two independent experiments 
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specially considering the previously presented results on the potential of PI3K 
inhibitors in this setting. It will be of interest to in future test whether PI3K inhibitors 
may prevent death of the animals over-expressing IL-10.	
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4.2.3. Prolonged IL-10 Expression Caused Pronounced Alterations 
in the Skin Histology 
 
 To systematically characterize the impact of IL-10 overexpression in pMT-10 
mice at the time of death, the histological analysis of various organs was performed 
(Figure 20 and 21). Firstly, we analyzed the spleen architecture. In line with previous 
data from our lab, the spleen lacked its characteristic organization (Figure 20). Then, 
given the fundamental role of IL-10 in gut homeostasis and our own findings showing 
that the gut is a major IL-10 producer in the induced pMT-10 model (A. Cardoso, 
unpublished data), we analyzed the histology of this organ. As observed in Figure 20, 
	
Figure 20. IL-10 overexpression leads to splenic histological disorganization, do not affect 
the gut histology and drives marked changes in the skin histology. The spleen, gut and skin of 
mice control (left panel) or IL-10 overexpressing (right panel) mice were analyzed by H&E staining 
60 days post zinc induction. Splenic disorganization, with loss of white and red pulp areas, is visible 
upon IL-10-induced overexpression. No obvious histological abnormality was found in the gut of 
control versus induced pMT-10 mice. Skin histology displayed pronounced alterations in mice over-
expressing IL-10. Represented are the histologies from one mouse per group, from a total of 12, in 
two independent experiments.	
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the gut did not show any obvious histological abnormality when comparing control 
and induced pMT-10 mice, thus discarding the involvement of this organ in the 
sudden death of the animals. In the same line, the histological analysis of the liver 
and the heart did not display any significant difference between induced and control 
pMT-10 (data not shown). 
The most striking phenotypic difference when comparing the histology from 
control and induced pMT-10 was found on the skin (Figure 21 and 22) The histologic 
analysis of the skin allows the distinction between its three main layers: epidermis, 
dermis and hypodermis. The outer portion – epidermis – is formed mainly by 
keratinocytes (around 90%); the epidermis layer also comprises the pilosebaceous 
unit, consisting of hair, hair follicle, sebaceous gland, and arrector pili muscle. As 
shown in Figure 21, the hair follicle is severely compromised on induced pMT-10. 
Aged dermis tends to become atrophic (134), with a decrease in fibroblasts and 
subdermal adipose tissue (Figure 21). Another characteristic difference among aged 
individuals is the increase in sebaceous glands (134), despite the decrease in sebum 
production. Similar alterations are observed in induced pMT-10 mice as can be 
observed in Figure 22. 
Figure 21. Sustained IL-10 overexpression induces marked changes in the skin histology. The 
skin of control (top panel) or pMT-10 mice over-expressing IL-10 (bottom panel) were analyzed by H&E, 
when mice over-expressing IL-10 were terminally ill. Changes in the skin architecture include an atrophy 
of the hair follicles (indicated by arrows), shrinking of the dermis (indicated by white lines) and decrease 
in subdermal adipose tissue (indicated by black lines). These phenotypic alterations are characteristic of 
an aged individual. The animals used had the same age. Represented one mouse per group, from a 
total of 12, in two independent experiments.	
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In line with the aforementioned skin histological alterations, pMT10 animals 
over-expressing IL-10 present at some point alterations in their physiognomy, most 
noticeable alopecia and grey hair, whereas control animals with the same age keep a 
normal phenotype (Figure 23). Moreover, the induced pMT-10 animals show signs of 
debilitation, and present a hatch up posture – which is an indication of pain and 
distress for laboratory animals. 
									 	
Figure 23. Induced pMT-10 mice present progeroid characteristics upon sustained IL-10 
overexpression. Long period of IL-10 induction in pMT-10 mice induces alterations in the animal 
physiognomy, being the most evident the loss of fur, debilitated appearance and hatch up posture. 
The picture on the left represents a non-induced control pMT-10 mice; the picture on the right 
represents an induced pMT-10 mice. Both were of the same age. Represented one mouse per 
group, from a total of 12, in two independent experiments. 
								
Figure 22. Sustained IL-10 overexpression induces changes in sebaceous glands. H&E skin 
histology of control (left panel) and IL-10 over-expressing (right panel) mice show augmented size of 
the sebaceous glands (indicated by black circles) in zinc-induced pMT-10 mice, a feature associated 
with aging. Control pMT-10 mice appear to have normal sebaceous glands. The animals used had 
the same age. Represented are of one mouse per group, from a total of 12, in two independent 
experiments. 
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 In all, in the presence of sustained IL-10, the animals present signs of 
premature aging. These include shorter lifespan, lordokyphosis, alopecia with 
atrophy of the hair follicle, increased sebaceous glands size, thinner dermis and 
thinner subcutaneous fat cell layers. Notably, these characteristics are among those 
described as features of an aged individual (Van Deursen et al.)(135). Importantly, 
the hematopoietic alterations seen in pMT10 mice overexpressing IL-10 also match 
the characteristics of an aged hematopoietic system, with a bias for the myeloid 
lineage (81). Future work will assess the presence of other characteristics possibly 
induced by IL-10, such as bilateral cataracts, muscle atrophy, diminished ability to 
repair wounds, and also a characterization of the hair follicle stem cells often 
associated with age-dependent alterations. 
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4.2.4. IL-10 as a Promoter of Accelerated Aging 		
 Abide by the previous results, where IL-10 overexpression induced the 
development of progeroid-like features, we questioned if IL-10 was potentiality 
accelerating aging. To address this question, we resorted to an in vitro model where 
cellular senescence can be monitored at the molecular level. 
 With advancing age, senescent cells accumulate in the healthy, injured, or 
remodeling tissues; moreover, senescent cells are also found in affected tissues of 
individuals with age-related diseases. A method commonly used to evaluate 
senescence is to measure the senesce-associated β-galactosidase (SA β-gal) 
activity (136). SA- β-gal activity is encoded by the lysosomal β-galactosidase gene. 
Cells usually express lysosomal β-galactosidase activity at a pH of 4.0, but at a pH of 
6.0 only senescent cells display β-gal activity. Moreover, the protein levels for 
lysosomal β-galactosidase increase during senescence. Based on this, we 
stimulated in vitro cultures of mouse embryonic fibroblasts (MEFs) from BL6 mice, 
with 10ng/mL of recombinant IL-10 (rIL-10) (Figure 24). As a control, MEFs not 
treated with rIL-10 were included. Fourty-eight hours later, cells were fixed and 
stained to detect β-gal activity.  Interestingly, addition of 10ng/mL of rIL-10 
programmed MEFs into senescence, with a percentage of around 6% associated 
with the presence of more than 10 β-gal-containing lysosomes per cell. This is the 
threshold normally used to undoubtedly consider cells to be senescent. 
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 We next started to investigate the mechanisms and signaling pathways 
involved in IL-10-induced cellular senescence. A well-characterized senescence-
activating molecular cascade is that mediated by the tumor suppressor p53, which 
leads to the activation of p21 (137). In fact, p21 is a marker for cell cycle arrest, 
associated with the inhibition of cellular proliferation (137). As such, the lack of DNA 
replication, due to the inhibition of proliferation, is itself a good marker for 
senescence and can be measured by ki67 expression. To investigate possible 
molecular mechanisms for IL-10-induced senescence in MEFS, we stimulated the 
cell cultures with rIL-10 for 48 hours, as before. At that time point, the cells were fixed 
and stained with fluorescent antibodies for p21 and ki67, to assess cell cycle arrest 
and DNA replication, respectively. Results were obtained in the IN Cell Analyzer 
2000 and automatically analyzed with the equipment software, by establishing 
brightness, contrast and intensity thresholds to distinguish positive from negative 
cells. Preliminary results showed that IL-10-treated MEFs displayed an increase in 
p21 activation, when compared to non-treated control, indicating that IL-10 is acting 
	 	
Figure 24. Recombinant IL-10 induces senescence in mouse embryonic fibroblasts. Mouse 
embryonic fibloblasts (MEFs) were cultured in the absence or presence of 10ng/mL of recombinant IL-
10. Fourty-eight hours later, the SA-β-gal activity was measured by immunofluorescence to determine 
senescence. On the left, illustrative image of two senescent cells out of four, after undergoing treatment 
with IL-10. The quantification of each cell with positive dots for β-gal-activity (green) is represented in the 
graph on the right. A cell was considered to be senescent when display more 5 positive lysosomes for β-
gal-activity. Represented is one experiment performed. 
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via p21 (Figure 25). As for ki67 detection, no differences were found, independently 
on the dose of rIL-10 used (Figure 24A). Having in consideration that our 
aforementioned results suggest that IL-10 signals through PI3K, and being PI3K a 
pathway essential to cell survival and proliferation, it is possible the existence of a 
conflicted signaling pattern, on one hand activating senesce through p21 and on the 
other hand sustaining cell survival. 
 
 
 The fact that TGFβ is reported to trigger senescence in a paracrine manner 
(138), and IL-22 – a cytokine of the family of IL-10 – being evidenced to promote 
senescence in HSCs (139), fuels the hypothesis that IL-10 is a player in organism 
aging. Further studies will be performed to further investigate the molecular pathways 
activated by IL-10 and leading to cellular senescence. These include p16, due to its 
relevance in senescence and since it is independent of p53 cascade (137), and the 
autophagic profile of the cells. Given the importance of PI3K pathway in our work, we 
will monitor the activation of the PI3K cascade in MEFs in the presence or absence 
of IL-10 and test its functional relevance by chemically inhibiting it. 
 
 
 
	
	
Figure 25. Recombinant IL-10 alters the p21 signaling cascade in mouse fibroblasts. The 
percentage of ki67 and p21 positive cells in MEF cultures was determined by immunofluorescence 
upon stimulation with 0, 10 or 50ng/mL of rIL-10 for 48h. Data are presented as the mean ± SEM; 
*** represent p value ≤ 0.001; One-way ANOVA test. SEM, standard error of the mean. 
Represented is one experiment performed. 
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4.2.5. Placing IL-10 as a Modulator of Hematopoietic Senescence: 
Future Perspectives 
 
Aging, defined as a time-dependent loss of physiological functional integrity, 
is a natural process that affects every system and every organism. A better 
understanding of the mechanisms driven by aging is crucial to assure a better life 
style (140). Of importance, the process of hematopoietic immunesenescence should 
be extensively studied, since a deteriorated hematopoiesis has life-threatening 
consequences (80). Our animal model for IL-10 overexpression has features that 
resemble the phenotypic traits of an aged hematopoiesis, characterized by impaired 
lymphopoiesis and increased myelopoiesis. Those reports drove us to hypothesize a 
possible role for IL-10 in aging. With that purpose, we established a systematic study 
for prolonged IL-10 overexpression, and an in vitro study to determine the extent of 
IL-10 action. Altogether, our results established that IL-10 is able to induce 
premature aging in the pMT-10 model, and senescence in fibroblasts cell cultures 
targeting the activation of p21 – a marker for senescence and cell cycle arrest. 
Upcoming work needs to performed in order to thoroughly characterize the 
induced pMT-10 model, by examining other progeroid features such as the 
development of bilateral cataracts and the diminished ability to repair wounds. Given 
the intrinsic association between aging and thymus involution, our group is also 
interested in investigating the process in induced pMT-10 mice, to determine if IL-10 
overexpression accelerates the phenotype. Moreover, focusing on the skin, it is of 
relevance to assess the activation of p21 also in MEFS of pMT-10 mice, by 
administering zinc throughout the pregnancy and establishing a MEF primary cell 
culture of the progeny. Other signaling cascades may play a role, particularly p16 – a 
canonical mediator of senescence independent of the p21 pathway (137). 
Furthermore, it is of interest to investigate the activation of autophagic programs. 
The significance of the PI3K signaling cascade in the pMT-10 mouse model 
was determined by the administration of a PI3K inhibitor in the animals over-
expressing IL-10 (chapter 4.1 of the thesis). Moreover, other reports show that p53-
p21 signaling pathway can be activated through PI3K (141). This suggests that PI3K 
might be involved in the IL-10 induced senescence; therefore it is crucial to evaluate 
PI3K activation also in MEF cell cultures, allowing a corroboration with the in vivo 
model.  
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Finally, once established a clear role for IL-10 in inducing senescence, our 
groups aims to try to revert it at molecular level; thus revealing the alterations 
imposed by IL-10 to the progression of the cell cycle, during the process of 
immunesenescence. Figure 26 presents a schematic illustration of the purposed 
model for IL-10 in promoting premature aging. 
 
 
																													 	
Figure 26. Which signaling cascades are implicated in IL-10 induced senescence? 
Preliminary work in MEF cultures suggests that IL-10 induces cell senescence via p21. 
Given the relevance of PI3K signaling, we hypothesize that response to IL-10 is made via 
PI3K, leading to subsequent activation of p21. Hereinafter, we will also study a possible 
role for p16 in IL-10-induced senescence. 
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5. Final Conclusion 
 
IL-10 is an important anti-inflammatory cytokine now evidenced to affect 
hematopoiesis by shifting cell differentiation towards myelopoiesis and likely involved 
in cellular senescence. It is tempting to speculate that these findings are actually 
related, and as such, in addition to the future plans to further address each of these 
findings, we also plan to pursue them in an integrated way. 
Hematopoiesis is a highly regulated process, which accompanies all changes 
of the organism (7). Moreover, any inadequacy during cell differentiation programs 
can lead to an overall deregulation, culminating in life-threatening pathologies. 
Findings from the current thesis place the pMT-10 mouse of IL-10 overexpression as 
a possible model for CMML, due to its hematological features. Of interest, CMML is a 
disease more prone to be developed in older individuals (132), in line with the other 
age-related features found in this model. The striking hematologic results, the shorter 
life-span and skin histology strongly raise the possibility of the induced pMT-10 
showing a progeroid syndrome. This may be linked to IL-10-driven senescence, 
since senescent cells drive age-related pathologies. Preliminary results conducted in 
vitro suggest that in fact IL-10 induced senesce via p53-p21 signaling cascades. 
These observations offer IL-10 a broader importance within organism homeostasis, 
now placing it as a modulator of (anti-) inflammaging and immunosenescence. 
Importantly, there are precedents in the literature linking anti-inflammatory cytokines 
with senescence, as studies on mesonephros and endolymphatic sac, during 
development, found that p21 upregulation, and consequent cell senescence, are 
controlled by TGFβ-SMAD and PI3K-forkhead box protein O pathways (142). 
Moreover, another member of the IL-10 family, IL-22, has also been described to 
promote senescence in HSCs (139). Thus, our findings and others in the literature 
fuel the hypothesis that IL-10 may be a player in organism aging. 
Immunosenescence is described as the process that the hematopoietic 
system undergoes with aging, which leads to increased susceptibility to infectious 
diseases, anemias, autoimmune diseases, and even cancers (80, 143). Among 
these alterations are the diminished number of naïve T cells; increased number of 
myeloid precursors (which sometimes originates neoplasms); decreased functional 
capacity of mature myeloid cells; and increased number of HSCs, but with loss of 
regenerative capacity (81). Understanding the mechanisms driving 
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immunosenescence, associated with aging, is of great interest considering the 
current demographic shift towards aged individuals, and also the association of many 
diseases – of neoplastic or neurodegenerative nature – with advanced aging. Given 
the role of IL-10 in myelopoiesis and as a promoter of senescence that we now 
present, studying IL-10 in the context of immunosenescence might guide future 
therapeutic strategies for aged-associated hematologic diseases. 
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7. Annexes 
 
The poster presented at SPI – Sociedade Portuguesa de Imunologia – annual 
meeting XLII 2016 entitled “Immunity, From Cells to Organisms” follows as an annex. 
The poster reflects the work developed during the second part of my thesis (chapter 
4.2). 
	
	
